Drug interactions between proton pump inhibitors and antiretroviral drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 2, 2007, Pages 197-207

  McCabe, Sarah M ^a   Smith, Patrick F ^a   Ma, Qing ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antiretrovirals; Drug interactions; HIV; Proton pump inhibitors

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ESOMEPRAZOLE; ETRAVIRINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LANSOPRAZOLE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OMEPRAZOLE; PANTOPRAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ANTIULCER AGENT; PROTON PUMP;

ACHLORHYDRIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FOOD; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW; SELF MEDICATION; SINGLE DRUG DOSE; STOMACH PH; STRESS ULCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD; VIRUS RESISTANCE; ANIMAL; DRUG COMBINATION; DRUG INTERACTION; METABOLISM;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTI-ULCER AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROESOPHAGEAL REFLUX; HIV INFECTIONS; HUMANS; PROTON PUMPS;

EID: 34547180378     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.2.197     Document Type: Review

References (59)

1. NO AUTHORS LISTED: ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am. J. Health Syst. Pharm. (1999) 56(4):347-379.
2. FRENKEL LM, TOBIN NH: Understanding HIV-1 drug resistance. Ther. Drug Monit. (2004) 26(2):116-121.
3. PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
4. LUCAS GM: Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J. Antimicrob. Chemother. (2005) 55(4):413-416.
5. FELLAY J, MARZOLINI C, MEADEN ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.
6. LUBER A, GARG V, GHARAKHANIAN S et al.: Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART [294]. In: Seventh International Congress on Drug Therapy in HIV Infections. Glasgow, UK (2004).
7. BLUM RA, SHI H, KAROL MD et al.: The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin. Ther. (1997) 19(5):1013-1023.
8. HATLEBAKK J: Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment. Pharmacol. Ther. (2003) 17(Suppl. 1):10-15.
9. a and metabolism. Aliment. Pharmacol. Ther. Symp. (2006) 2:340-350.
10. ROBINSON M, HORN J: Clinical pharmacology of proton pump inhibitors; what the practsing physician needs to know. Drugs (2003) 63:2739-2754.
11. Aciphex®. Product Information. Eisai, Inc., Teaneck, NJ, USA (2003).
12. MCCOLL KE, KENNERLEY P: Proton pump inhibitors - differences emerge in hepatic metabolism. Dig. Liver Dis. (2002) 34(7):461-467.
13. MINER P Jr, KATZ PO, CHEN Y, SOSTEK M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. (2003) 98(12):2616-2620.
14. ROHSS K, HASSELGREN G, HEDENSTROM H: Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. (2002) 47(5):954-958.
15. HOETELMANS R: Clinical pharmacokinetics of antiretroviral drugs. AIDS Rev. (1999) 1:167-178.
16. Reyataz®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2006).
17. TOMILO DL, SMITH PF, OGUNDELE AB et al.: Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (2006) 26(3):341-346.
18. AGARWALA S, GRAY K, WANG Y, GRASELA D: Pharmacokinetic effect of omperazole on atazanavir co-administered with ritonavir in healthy subjects. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
19. KISER JJ, LICHTENSTEIN KA, ANDERSON PL, FLETCHER CV: Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 26(4):511-514.
20. KOSEL BW, STOREY SS, COLLIER AC: Lack of interaction between atazanavir and lansoprazole. AIDS (2005) 19(6):637-638.
21. ANTONIOU T, YOONG D, BEIQUE L et al.: Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J. Acquir. Immune Defic. Syndr. (2005) 39(1):126-128.
22. WINSTON A, BLOCH M, CARR A et al.: The clinical correlation's of trough plasma atazanavir concentrations in a cohort of HJV-1 positive individuals receiving HAART. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
23. LUBER A, BROWER R, RELOQUIN C, FRANK I: Steady state pharmacokinetics of QD fosamprenavir/ritonavir and atazanavir/ritonavir in combination with 20mg QD omperazole in healthy volunteers. Presented at: The 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
24. AGARWALA S, ELAY T, CHILD M et al.: Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada. (2005) Abstract 11.
25. O'MARA E, PILIERO P, DRUSANO G et al.: BMS-32632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor naïve HIV+ population. AIDS (2000) 14(Suppl.4):S19.
26. TABURET AM, PC, CHAZALLON C et al.: Interactions between atazanavir/ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
27. AGARWALA S, RUSSO R, MUMMANENI V EA: Steady state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [abstract no H1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
28. Prezista®. Product information. Tibotec, Bridgewater, NJ, USA (2006).
29. SEKAR V, HOETELMANS R, DE MAREZ T, DEPAUW M et al.: Pharmacokinetics of TMC-114: effect of omeprazole and ranitidine. International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janerio, Brazil (2005).
30. Lexiva®. Product information. GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
31. FURFINE ES, BAKER CT, HALE MR et al.: Preclinical pharmacology and pharmacokinetics of GW-433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. (2004) 48(3):791-798.
32. SHELTON MJ, FORD SL, BORLAND J et al.: Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr. (2006) 42(1):61-67.
33. FORD SL, WIRE MB, LOU Y, BAKER KL, STEIN DS: Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob. Agents Chemother. (2005) 49(1):467-469.
34. Crixivan®. Product information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2004).
35. BURGER DM, HUGEN PW, KROON FP et al.: Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS (1998) 12(15):2080-2082.
36. LIN JH, CHEN IW, VASTAG KJ, OSTOVIC D: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. (1995) 23(7):730-735.
37. Videx®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2000).
38. BERTZ R, CHIU Y, NAYLOR C, LUFF K, BRUN S: Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Presented at: The 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
39. Kaletra®. Product information. Abbott Laboratories, North Chicago, IL, USA.
40. KLEIN C, CHIU Y, CAI Y et al.: Lack of effect of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir Tablet. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006).
41. Invirase®. Product information. Roche Laboratories, Inc., Nutley, NJ, USA (2005).
42. WINSTON A, BACK D, FLETCHER C et al.: Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS (2006) 20(10):1401-1406.
43. KAKUDA TN, FALCON RW: Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy (2006) 26(8):1060-1068.
44. Aptivus®. Product information. Boehringer Ingelheim, Ridgefield, CT, USA (2006).
45. HEESWIJK REA: The pharmacokinetic interactions between tipranavir/ ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP 3A4 in healthy volunteers. Presented at: The 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy (2004).
46. Rescriptor®. Product information. Pfizer, Groton, CT, USA (2006).
47. SHELTON MJ, HEWITT RG, ADAMS JM et al.: Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J. Clin. Pharmacol. (2003) 43(2):171-179.
48. LAKE-BAKAAR G, QUADROS E, BEIDAS S et al.: Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1988) 109(6):502-504.
49. WELAGE LS, CARVER PL, REVANKAR S, PIERSON C, KAUFFMAN CA: Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21(6):1431-1438.
50. SHELTON MJ, ADAMS JM, HEWITT RG, MORSE GD: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin. Infect. Dis. (1998) 27(4):739-745.
51. SHAFFER RT, LAHATTE LJ, KELLY JW et al.: Gastric acid secretion in HIV-1 infection. Am. J. Gastroenterol. (1992) 87(12):1777-1780.
52. OLMOS M, ARAYA V, PSKORZ E et al.: Coinfection: Helicobacter pylori/human immunodeficiency virus. Dig. Dis. Sci. (2004) 49(11-12):1836-1839.
53. PISCATELLI S, BAEDE P, DEGIER K, VAN'T KLOOSTER G, GRAHAM N: Pharmacokinetics of TMC-125 in HIV infected patients and healthy volunteers. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, USA April (2002).
54. GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYA E et al.: A randomized, double-blind, placebo-controlled trial of TMC-125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS (2003) 17(17):2487-2494.
55. GYURE-SCHOLLER M EA: TMC-125 bioavailability is not affected by ranitidine and omeprazole. International AIDS Society. Toronto, Canada (2006).
56. BACK D, GATTI G, FLETCHER C et al.: Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (2002) 16(Suppl. 1):S5-S37.
57. GERBER JG, ACOSTA EP: Therapeutic drug monitoring in the treatment of HIV infection. J. Clin. Virol. (2003) 27(2):117-128.
58. CLEVENBERGH P, MOULY S, SELLIER P et al.: Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinicians point of view. Curr. HIV Res. (2004) 2:309-321.
59. FELLAY J, MARZOLINI C, MEADEN ER et al.: Repsonse to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.